格林美(002340.SZ):擬擴大印尼三元前驅體產能
格隆匯1月3日丨格林美(002340.SZ)公佈,迄今為止,公司年產3萬噸高鎳動力電池三元前驅體材料項目已經建成竣工,並已經全部獲得中長期全球客户訂貨,為了滿足全球客户的新增需要,公司計劃將年產3萬噸高鎳動力電池三元前驅體材料項目的產能由3萬噸擴大為5萬噸,項目的實施主體名稱仍然為PT INDONESIA QINGMEI ENERGY MATERIALS(以下簡稱“QINGMEI”),格林美(江蘇)持有QINGMEI 99%的股權,NEW HORIZON INTERNATIONAL HOLDING LIMITED持有QINGMEI 1%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.